Essa Pharma halted its Phase II clinical trial of masofaniten, a treatment for prostate cancer, based on an interim review. The study was evaluating masofaniten in combination with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC). The interim review showed a higher-than-expected PSA90 response rate in patients receiving only enzalutamide and no clear benefit when masofaniten was added. A futility analysis indicated a low probability of the combination treatment achieving the study’s primary endpoint. While the trial was stopped, the combination of masofaniten and enzalutamide was well-tolerated.

Source.